Mark Leick

MD | Assistant Professor at HMS | MGH Bone Marrow Transplantation and Cellular Therapy | Leick Lab | @OslerHousestaff 2014-2017

[Bryan D. Choi MD PhD @BryanDChoi]

Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter!
https://t.co/ZaDjvVAms7

[Eli Darnell, MD @EliDarnellMD]

https://t.co/raJMCjXCwJ
Amazing findings coming out of the Maus lab! Great step forward to GBM treatment. Congrats to all the authors on their incredible work.

[Majzner_Lab @Majzner_Lab]

Excited to share that @Majzner_Lab is moving to @DanaFarber @DFBC_PedCare as of Sept. Bittersweet to leave Stanford, but looking forward to growing our research program both in the lab and in the clinic. Hiring postdocs, scientists & lab manager- please reach out if interested!

[Klebanoff_Lab @KlebanoffLab]

🚨Next-level T cell engineering enters the clinic! DNA base editor to simultaneously silence CD7 (minimize fratricide), TCRB (minimize GVHD), and CD52 (host pre-conditioning) in allo CD7 CAR-expressing T cells for T-ALL. No DNA cuts, no translocations.
https://t.co/R579E4p1zk

[Majzner_Lab @Majzner_Lab]

Really happy to see the wonderful work from colleagues in Rome using 3rd gen GD2 CARs for neuroblastoma. This is the largest series of CAR T responses in a solid tumor to date & the fact that it’s in a pediatric cancer is awesome! Bravo! https://t.co/6hlek3uKTi

[Mark Leick @Mark_Leick]

CAR-T coming for a non-malignant indication near you

https://t.co/B8lPkyq6VD.

[Majzner_Lab @Majzner_Lab]

Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. https://t.co/EKzcX4JaFP

[NatureRevClinOncol @NatRevClinOncol]

'Multiomics STEP up in correlative analysis of response to CAR T cells'. In this article, Mark Leick & Marcela Maus discuss the potential of cfDNA-based analyses to inform on CAR T cell expansion kinetics & tumour-infiltration patterns in patients: https://t.co/IfD0SeOhPI

[Nathan Singh @NathanSinghLab]

We are hiring! Interested in engineering, genomics and T cell therapies for cancer? Want to work with awesome people? Looking for a great place to live? Come join us in St Louis!

More info about us here: https://t.co/XBPAtufqhQ

Apply here: https://t.co/XCUTai6BcP

Please RT!

[Michael Jain @MichaelDJain]

Great talk on germline HLH variants affecting CAR-T toxicity by @Mark_Leick @MarcelaMaus , looking forward to collaborating! #ASH22 @DrFredLocke

[Mark Leick @Mark_Leick]

Hope you picked up your badge at the airport… 😬#ASH22

[Frederick L. Locke @DrFredLocke]

If you assumed we are talking about CAR-T, you would be correct! @jaepark @MarcelaMaus @Mark_Leick #ASH22

[Saheli Sadanand @SaheliSadanand]

Thoughtful piece in @NatureMedicine from @Eddie_Cliff, Reid Merryman, Philippe Armand and Caron Jacobson @harvardmed @DanaFarber on #CARTcells in #DLBCL. Thanks for writing this! #lymphoma #lymsm

[Nick Vitanza @VitanzaNick]

We're excited to share the 1st clinical experience delivering intracranial B7-H3 #CARTcells to treat #DIPG in @CD_AACR, a journal of the @AACR. #1: on behalf of @seattlechildren & @SCTherapeutics, we are humbled by our patients' trust and bravery. (1/2)
https://t.co/UmNcuPwC8Z

[ACIR @ACIR_org]

SPOTLIGHT: Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell #lymphoma @Mark_Leick @SatyenGohil @gaddyg @MarcelaMaus. Originally published in @NatureMedicine. To read our summary click https://t.co/3ToP5VPuQS and scroll all the way down.

[Toby Eyre @tobyeyre82]

Large propensity score matched study
#axicel vs #tisacel in @NatureMedicine by @BachyEmmanuel et al

Closely matched large cohorts
⬆️ ORR, CR, PFS & OS advantage for #axicel pts

1 yr OS 63.5% vs 48.8% p=0.0072

⬆️ G1-2 CRS, & all grade ICANS in #axicel pts
#CART #lymsm #DLBCL

[Mark Leick @Mark_Leick]

Unbelievably exciting to see the benefits of CAR-T being extended safely for non malignant conditions with high morbidity https://t.co/uFtSNJDQSU

[Mark Leick @Mark_Leick]

Its finally out @NatureMedicine ! Excited to share our work identifying an association between CAR-Tregs and relapse/resistance after CAR-T cell treatment in DLBCL via scRNAseq and then modeling it in vivo (along with much more!)

[Gad Getz Laboratory @getz_lab]

[1/6 🧵] Today @NatureMedicine! Cellular dynamics monitored over time at the #SingleCell level reveals new insights into why some patients with large B cell lymphomas respond better than others to #CARTcell therapy https://t.co/gYWybW7N8P

Read the main takeaways below 👇!

[Mark Leick @Mark_Leick]

@JohnRossMD I think our seasoned ICU nurse even panicked a bit when this popped up while titrating pressors...

[Mark Leick @Mark_Leick]

Thrilled to kick off the 10th Annual Industrial Symposium in Montpellier with the keynote lecture this morning!